EirGenix Inc

EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.